The US and Canada have healthcare, life science and medical device industries that are complex and interconnected.

On March 6, President Donald Trump instituted a 25 percent ad valorem rate of duty on goods imported from Canada under the International Emergency Economic Powers Act.[1] The tariffs will not be implemented on goods that comply with the United States-MexicoCanada Agreement until April 2.[2] In turn, Canada has announced a $155 billion tariff package on the US.[3]

Download the full Law360 article, "Mitigating Tariff Risks For Healthcare In US And Canada."



Contacts

Jeff Wurzburg
Jeff Wurzburg
Partner
Email
jeff.wurzburg@nortonrosefulbright.com
T: +1 210 270 9338
Vanessa Grant
Vanessa Grant
Senior Partner
Email
vanessa.grant@nortonrosefulbright.com
T: +1 416 216 4056

Practice areas:

Industry:

Recent publications

Norton Rose Fulbright | CMMI resets value-based care landscape

Publication

CMMI resets value-based care landscape

Value‑based care is entering its next phase as the Trump administration seeks accountability.

United States | November 21, 2025

Healthcare
Cryptocurrency

Publication

Blockchain law: ‘In rem’ and ‘quasi’ in rem jurisdiction in digital assets disputes

When ordinary in personam jurisdiction is not available in a dispute about digital assets, is there room for other kinds of personal jurisdiction, such as in rem and quasi in rem jurisdiction?

United States | November 20, 2025

FinTech
Norton Rose Fulbright | How Nasdaq, SEC proposals may transform listing standards

Publication

How Nasdaq, SEC proposals may transform listing standards

The Nasdaq Stock Market LLC filed two proposals with the US Securities and Exchange Commission.

United States | November 19, 2025

Capital markets
Site search

Subscribe and stay up to date with the latest legal news, information and events . . .

Subscribe now